search
Back to results

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

Primary Purpose

Venous Thromboembolism, Arterial Thromboembolism

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
IMPROVE DD VTE Tool
Sponsored by
Northwell Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Venous Thromboembolism

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

• Patients with an acute medical illness and ONE of the following risk factors:

  • Age > 60 years
  • Presence of known thrombophilia
  • Intensive care unit (ICU)/coronary care unit (CCU) stay
  • Lower extremity paralysis
  • Cancer
  • Immobilization
  • Previous VTE history
  • D-dimer (>2X ULN)

Exclusion Criteria:

• Patients with the following factors:

  • Therapeutic anticoagulation
  • History of recent bleeding.
  • Active gastroduodenal ulcer
  • Thrombocytopenia (admission platelet count< 75x 109 cells/L )
  • Coagulopathy (baseline INR > 1.5)
  • Severe renal insufficiency (baseline)CrCl < 30ml/min)
  • Dual antiplatelet therapy
  • Bronchiectasis/pulmonary cavitation
  • Active cancer, and recent major surgery within 30 days of their index hospitalization bleeding.

Sites / Locations

  • North Shore University Hospital
  • The Institute for Health Innovations and Outcomes Research
  • Long Island Jewish Medical Center
  • Lenox Hill Hospital
  • Staten Island University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Usual Medical Care

"SMART on FHIR" application of the IMPROVE DD VTE CPR

Arm Description

As per standard of care

This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients. Health outcomes and health resource utilization will be assessed for the duration of patient hospitalization until 90 days post-discharge by review of health records. 2 hospitals will be randomized to the experimental arm and 2 hospitals will be randomized to the No Intervention arm.

Outcomes

Primary Outcome Measures

To evaluate the impact of implementing a multicenter QI program using a universal for type and duration of thromboprophylactic agent
Specifically, our pilot study will determine if this QI intervention will result in a greater increase in the proportion of at-VTE or high-VTE risk medical patients that are treated with an appropriate thromboprophylactic agent, both during hospitalization and in the post-hospital discharge period using a 5-point score where 0-1 constitutes low VTE risk, 2-3 constitutes moderate VTE risk, and 4 constitutes high VTE risk.

Secondary Outcome Measures

Rates of patient VTE as assessed by the diagnostic and imaging codes for VTE
Change in patient rates of VTE - lower extremity deep vein thrombosis (DVT) or PE using objective testing at up to 90 days and VTE-related death by autopsy or objective criteria (ICD codes and CPT diagnostic codes as per Appendix 2).
Number of participants with VTE-related readmissions
The combined total number of VTE-related readmissions of patients at up to 90 days.
Number of participants with all cause readmissions
The combined total of the number of patients with all cause hospital readmissions.
Change in diagnosis-related group
Change in diagnosis-related group of patients from baseline up to 90 days.
Change in type of insurance
Change in type of insurance for patients from baseline up to 90 days.
Change in drug cost
Change in drug cost for patients from baseline up to 90 days.
Change in prescriber patterns of LMWH (low molecular weight heparin)
Change in prescriber patterns for patient use of LMWH, enoxaparin, compared to standard of 40mg SQ QD.
Change in prescriber patterns of UFH (unfractionated heparin)
Change in prescriber patterns of patient use of UFH, as compared to standard of 5000U SQ BID or TID.
Change in prescriber patterns of fondaparinux
Change in prescriber patterns of patient use of fondaparinux, as compared to standard of 2.5mg SQ QD.
Change in prescriber patterns of rivaroxaban
Change in prescriber patterns of patient use of direct oral anticoagulant, rivaroxaban, as compared to a standard of 10mg PO QD.
Arterial thromboembolism (ATE)
including stroke, transient ischemic attack (TIA), myocardial infarction (MI)
Total thromboembolism (VTE and ATE)
Including stroke, transient ischemic attack (TIA), myocardial infarction (MI) systemic embolism, acute limb ischemia, lower extremity deep vein thrombosis (DVT).

Full Information

First Posted
February 1, 2021
Last Updated
July 29, 2022
Sponsor
Northwell Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04768036
Brief Title
A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients
Official Title
A Multicenter Randomized Study of a Universal Electronic Health Record-based IMPROVE-DD VTE Risk Assessment Model Implementation as a Quality Improvement Project for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
December 21, 2020 (Actual)
Primary Completion Date
January 21, 2022 (Actual)
Study Completion Date
January 21, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwell Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE DD VTE clinical prediction rules (CPRs) with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients. The patient population will consist of hospitalized, medically ill (non-surgical, non-obstetrical) individuals aged > 60 years.
Detailed Description
Investigators, plan to do a study using a pragmatic, randomized design as part of a Quality Improvement (QI) project as a substudy within the existing NIH R18 proposal of creating a universal "SMART on FHIR" platform of the IMPROVE VTE CPR for key Northwell Health hospitals. Investigators, aim is to assess whether an EHR-embedded CPR for VTE prevention - the IMPROVE VTE CPR - ultimately tied to electronic order entry will increase the proportion of hospitalized medical patients at risk of VTE who receive appropriate thromboprophylaxis, both at hospital admission AND at hospital discharge, compared to UMC. Investigators, secondary aims are to assess whether key adverse outcomes such as symptomatic VTE and hospital readmission for VTE are reduced and whether health -resource utilization metrics are improved.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Thromboembolism, Arterial Thromboembolism

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A multicenter clustered randomized study of a universal electronic health record-based IMPROVE VTE risk assessment model implementation as a quality improvement project for the prevention of venous thromboembolism in hospitalized medically ill patients.
Masking
Care Provider
Allocation
Randomized
Enrollment
10699 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual Medical Care
Arm Type
No Intervention
Arm Description
As per standard of care
Arm Title
"SMART on FHIR" application of the IMPROVE DD VTE CPR
Arm Type
Experimental
Arm Description
This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients. Health outcomes and health resource utilization will be assessed for the duration of patient hospitalization until 90 days post-discharge by review of health records. 2 hospitals will be randomized to the experimental arm and 2 hospitals will be randomized to the No Intervention arm.
Intervention Type
Other
Intervention Name(s)
IMPROVE DD VTE Tool
Intervention Description
Universal "SMART on FHIR" platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow.
Primary Outcome Measure Information:
Title
To evaluate the impact of implementing a multicenter QI program using a universal for type and duration of thromboprophylactic agent
Description
Specifically, our pilot study will determine if this QI intervention will result in a greater increase in the proportion of at-VTE or high-VTE risk medical patients that are treated with an appropriate thromboprophylactic agent, both during hospitalization and in the post-hospital discharge period using a 5-point score where 0-1 constitutes low VTE risk, 2-3 constitutes moderate VTE risk, and 4 constitutes high VTE risk.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Rates of patient VTE as assessed by the diagnostic and imaging codes for VTE
Description
Change in patient rates of VTE - lower extremity deep vein thrombosis (DVT) or PE using objective testing at up to 90 days and VTE-related death by autopsy or objective criteria (ICD codes and CPT diagnostic codes as per Appendix 2).
Time Frame
90 days
Title
Number of participants with VTE-related readmissions
Description
The combined total number of VTE-related readmissions of patients at up to 90 days.
Time Frame
90 days
Title
Number of participants with all cause readmissions
Description
The combined total of the number of patients with all cause hospital readmissions.
Time Frame
90 days
Title
Change in diagnosis-related group
Description
Change in diagnosis-related group of patients from baseline up to 90 days.
Time Frame
90 days
Title
Change in type of insurance
Description
Change in type of insurance for patients from baseline up to 90 days.
Time Frame
90 days
Title
Change in drug cost
Description
Change in drug cost for patients from baseline up to 90 days.
Time Frame
90 days
Title
Change in prescriber patterns of LMWH (low molecular weight heparin)
Description
Change in prescriber patterns for patient use of LMWH, enoxaparin, compared to standard of 40mg SQ QD.
Time Frame
90 days
Title
Change in prescriber patterns of UFH (unfractionated heparin)
Description
Change in prescriber patterns of patient use of UFH, as compared to standard of 5000U SQ BID or TID.
Time Frame
90 days
Title
Change in prescriber patterns of fondaparinux
Description
Change in prescriber patterns of patient use of fondaparinux, as compared to standard of 2.5mg SQ QD.
Time Frame
90 days
Title
Change in prescriber patterns of rivaroxaban
Description
Change in prescriber patterns of patient use of direct oral anticoagulant, rivaroxaban, as compared to a standard of 10mg PO QD.
Time Frame
90 days
Title
Arterial thromboembolism (ATE)
Description
including stroke, transient ischemic attack (TIA), myocardial infarction (MI)
Time Frame
90 days
Title
Total thromboembolism (VTE and ATE)
Description
Including stroke, transient ischemic attack (TIA), myocardial infarction (MI) systemic embolism, acute limb ischemia, lower extremity deep vein thrombosis (DVT).
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Patients with an acute medical illness and ONE of the following risk factors: Age > 60 years Presence of known thrombophilia Intensive care unit (ICU)/coronary care unit (CCU) stay Lower extremity paralysis Cancer Immobilization Previous VTE history D-dimer (>2X ULN) Exclusion Criteria: • Patients with the following factors: Therapeutic anticoagulation History of recent bleeding. Active gastroduodenal ulcer Thrombocytopenia (admission platelet count< 75x 109 cells/L ) Coagulopathy (baseline INR > 1.5) Severe renal insufficiency (baseline)CrCl < 30ml/min) Dual antiplatelet therapy Bronchiectasis/pulmonary cavitation Active cancer, and recent major surgery within 30 days of their index hospitalization bleeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alex Spyropoulos, MD
Organizational Affiliation
Northwell Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
North Shore University Hospital
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Facility Name
The Institute for Health Innovations and Outcomes Research
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Facility Name
Long Island Jewish Medical Center
City
New Hyde Park
State/Province
New York
ZIP/Postal Code
11040
Country
United States
Facility Name
Lenox Hill Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States
Facility Name
Staten Island University Hospital
City
Staten Island
State/Province
New York
ZIP/Postal Code
10305
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21436241
Citation
Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AGG, Nakamura M, Piovella F, Kakkar AK, Spencer FA; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. doi: 10.1378/chest.10-1944. Epub 2011 Mar 24.
Results Reference
background
PubMed Identifier
28640324
Citation
Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 Aug 30;117(9):1662-1670. doi: 10.1160/TH17-03-0168. Epub 2017 Jun 22.
Results Reference
background

Learn more about this trial

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

We'll reach out to this number within 24 hrs